ArticleJournal of translational medicine2025

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.

Laura Scalambra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.